Getting burned by a vendor doesn’t always mean the vendor was entirely at fault. Medical practices must also take responsibility for defining the opportunity, conducting due diligence, establishing clear expectations, supporting implementation, and actively managing performance. This article explores the questions leaders should ask before blaming a vendor, and how to build more accountable, successful partnerships.

Ancillary services can improve access, strengthen care between visits, and create new revenue streams that help independent medical practices compete with larger healthcare systems. Yet many programs never achieve their clinical, operational, or financial potential. The problem is rarely the reimbursement opportunity alone. Underperformance usually begins with poor planning, weak leadership support, the wrong vendor or operating model, and fragmented execution. Here are the m

Healthcare organizations operate in one of the most complex employment and compliance environments in the country. Clinics, specialty practices, and healthcare groups are not simply managing payroll, benefits, hiring, and HR administration. They are also managing licensed clinical staff, employee credentialing, workforce turnover, HIPAA training, OSHA requirements, labor law exposure, patient privacy expectations, and the daily operational pressure of keeping care delivery mo

The GUIDE Model is one of the clearest signals that CMS wants dementia care to move from fragmented, visit-based treatment to structured, longitudinal care management. For neurology clinics, primary care groups, and health systems, the opportunity is not limited to organizations that were accepted into the initial CMS model cohort. Even if a clinic did not make the original cut-off, the strategic lesson remains the same: dementia care is moving toward care coordination, careg

Neurology clinics are entering a period where reimbursement strategy can no longer be built around a narrow set of office visits, procedures, and drug-administration economics. The warning signs are already visible. CMS has selected Botox/Botox Cosmetic for Medicare drug price negotiation, with negotiated prices scheduled to become effective January 1, 2028. While this is not a traditional physician fee schedule cut, it directly affects a therapy widely used across neurology,

For years, many nephrology practices have built their operating model around later-stage kidney disease: advanced CKD, dialysis preparation, transplant coordination, and high-acuity patient management. That work will remain essential. However, the clinical landscape is shifting. GLP-1 receptor agonists, particularly semaglutide, are now showing meaningful evidence in slowing chronic kidney disease progression, especially in patients with type 2 diabetes and CKD. The business